Acromegaly Pipeline Assessment, 2022 | Insights into the Emerging Therapies, Latest FDA, EMA, and PMDA Approvals, Ongoing Clinical Trials | Amryt (Mycapssa), Crinetics (Paltusotine), Camurus, Ionis

October 17 20:58 2022
Acromegaly Pipeline Assessment, 2022 | Insights into the Emerging Therapies, Latest FDA, EMA, and PMDA Approvals, Ongoing Clinical Trials | Amryt (Mycapssa), Crinetics (Paltusotine), Camurus, Ionis
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Acromegaly therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Acromegaly Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Acromegaly Market. 

The Acromegaly Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Acromegaly Pipeline Analysis

Acromegaly Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Acromegaly and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acromegaly market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 15+ products under different phases of clinical development –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Acromegaly Therapeutic Segment:

https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight

Acromegaly Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Acromegaly. Currently, Crinetics Pharmaceuticals has its Acromegaly drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Acromegaly Therapeutic Market Include

• Ionis Pharmaceuticals

• Crinetics Pharmaceuticals

• Camurus

• Ono Pharmaceutical

• Aquestive Therapeutics

• Strongbridge Biopharma

• Italfarmaco

• Ipsen

• Antisense Therapeutics

• Dauntless Pharmaceuticals

• TTY Biopharm

• Peptron

• DexTech Medical AB

• Rani Therapeutics

• OPKO Health, Inc.

• Amolyt Pharma

• Foresee Pharmaceuticals

• ADVANZ PHARMA

And many others

Acromegaly Emerging Drugs

• IONIS-GHR-LRX

• Paltusotine

• Octreotide Capsules

• ATL1103

• CAM2029

• Veldoreotide 

• CRN00808 

• Lanreotide PRF

And many more 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight

As per DelveInsight, the Acromegaly therapeutics market is expected to grow in the coming years owing to the increase in the prevalent pool, expected entry of emerging therapies with novel targets and attractive pricing, ongoing Research & Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Acromegaly Current Treatment Patterns

4. Acromegaly – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acromegaly Late Stage Products (Phase-III)

7. Acromegaly Mid-Stage Products (Phase-II)

8. Acromegaly Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acromegaly Discontinued Products

13. Acromegaly Product Profiles

14. Key Companies in the Acromegaly Market

15. Key Products in the Acromegaly Therapeutics Segment

16. Dormant and Discontinued Products

17. Acromegaly Unmet Needs

18. Acromegaly Future Perspectives

19. Acromegaly Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Acromegaly Market

“Acromegaly Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Acromegaly Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: